Related Experiment Videos
Hyperfibrinogenemia increases the risk of cardiac events after coronary artery stenting
A Germing1, S von Dryander, A Machraoui
1Department of Cardiology and Angiology, Berufsgenossenschaftliche Kliniken Bergmannsheil, University of Bochum, Germany. alfried.germing@ruhr-uni-bochum.de
Insights
Elevated fibrinogen levels may increase the risk of adverse cardiac events after coronary artery stenting. This finding suggests considering fibrinogen testing to improve patient outcomes following percutaneous coronary intervention.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Biology
Background:
- Percutaneous coronary intervention (PCI) success depends on various factors, including lesion characteristics and intervention-induced endothelial trauma.
- Endothelial trauma can activate procoagulatory factors, potentially leading to intraluminal thrombosis and adverse outcomes.
- Assessing pre-procedural patient factors is crucial for predicting outcomes after coronary stenting.
Purpose of the Study:
- To investigate the association between pre-procedural clinical, morphological, and laboratory features and adverse cardiac events after successful coronary artery stenting.
- To identify specific biomarkers that predict unfavorable outcomes in patients undergoing percutaneous coronary intervention.
- To evaluate the role of fibrinogen levels in relation to cardiac events post-stenting.
Main Methods:
- Analysis of 228 consecutive patients with coronary artery disease undergoing percutaneous intervention.
- Comparison of clinical, morphological, and laboratory (lipids, fibrinogen) data between patients with and without adverse cardiac events (stent thrombosis, myocardial infarction, urgent revascularization, death).
- Statistical analysis to determine significant differences in pre-procedural parameters between groups.
Main Results:
- A significantly higher level of fibrinogen was observed in patients experiencing adverse cardiac events compared to the control group.
- No significant differences were found in other laboratory parameters (cholesterol, triglycerides) or clinical characteristics between the groups.
- Hyperfibrinogenemia emerged as a potential predictor of adverse cardiac events post-stenting.
Conclusions:
- Hyperfibrinogenemia may be associated with an increased risk of adverse cardiac events following intracoronary stenting.
- Elevated fibrinogen levels should be considered in clinical practice when assessing patients for percutaneous coronary intervention.
- Further research may elucidate the causal mechanisms and therapeutic implications of this association.
Abstract:
Primary success rates, and the angiographic and clinical outcome after percutaneous coronary intervention, are influenced by many different factors. Clinical features and morphologic characteristics of the target lesion are important. Also, interventionally caused endothelial trauma may trigger atherogenetic and procoagulatory factors leading to intraluminal thrombosis. The study population consisted of 228 consecutive, unselected patients with symptomatic coronary artery disease or exercise-induced myocardial ischemia and coronary artery stenoses eligible for percutaneous intervention. We analyzed different clinical, morphological, and laboratory (total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglycerides, fibrinogen) features in those patients with adverse cardiac events (stent thrombosis, myocardial infarction, urgent target vessel revascularization, death) after primary successful coronary artery stenting, compared with a control group without adverse events. In the group with adverse cardiac events we found a significantly higher level of fibrinogen compared with the control group. Other laboratory data and clinical characteristics were not significantly different between the two groups. The study shows a possible association between hyperfibrinogenemia and adverse cardiac events after intracoronary stenting. In clinical practice, the potential role of elevated levels of fibrinogen in an unfavorable outcome after percutaneous coronary interventions should be considered when planning coronary artery stenting.